How I Overcame My 50-Year Struggle With Gynecomastia

Before we get started, here's a little story from one of my clients, Sammie Fields.
Hey there I’m Sammie.

I’m in my 70s now and I’m finally enjoying my life as a masculine-looking guy. I struggled with gynecomastia ever since puberty. Back in the day it was totally unheard of for a man to have breasts.

Man boobs were quite a rare thing. If you think having man boobs is bad now, try having them in the 60s. I spent my entire life in fear that someone would notice my breasts. I stayed away from women - I was horrified of the bedroom. I also stayed away from the beach and only got out wearing the thickest of clothing to try and conceal myself.

Back then there was no internet, and no information out there to help me. I tried everything I could to try and get rid of my man boobs. I lost weight and tried different diets but all to no avail.

One day however, just a few years ago I came across a newspaper article.

This article complained of how male fish in our waters were becoming feminized. Scientists had studied these male fish and found how they had developed feminine characteristics, even to the point of producing eggs! Apparently this was due to the prevalence of the female hormone estrogen in our water supply.

Apparently, due to most government water filtration systems (including the US), estrogen passes unfiltered right into our taps, and straight into your belly when you drink that glass of water.

The estrogen is being absorbed by us and is resulting in modern man having low sperm counts, fertility problems and gynecomastia. Heck it might even be responsible for the boom in the male cosmetics industry (joke).

So I went out there, did some research and found some other shocking sources of estrogen that exist especially in the modern environment, but were also there in the past albeit in much lower quantities and not as widespread back in the day.

Why am I telling you all this?

Well I lost my man boobs in my mid-sixties. The only way I managed to succeed was after I armed myself with the facts, and all the information I needed to know about the very root cause of my gynecomastia.

If I could get rid of my gynecomastia in my sixties, then I know for a fact that anyone else can do it too. So if you're about to give up or you have given up and are ready to face the world as a pseudo-man, then I'm here to tell you to wake up! Get out of that trance, shake yourself up and inform yourself of real working tactics that have been proven time and time again to help many thousands of guys lose their man boobs permanently using all-natural methods.

And I can't think of a better person to help you than my good friend Robert Hull. I leave you to his very capable hands and I'm sure that you will learn much on his new blog.

Wednesday, May 4, 2011

PRISTIQ(R) Extended Release Tablets Shown To Significantly Reduce Number And Severity Of Moderate-To-Severe Hot Flashes Associated With Menopause


Main Category: Menopause
Also Included In: Women's Health / Gynecology
Article Date: 04 May 2011 - 5:00 PDT email icon email to a friend � printer icon printer friendly � write icon opinions �

Current Article Ratings:


Patient / Public: not yet rated
Healthcare Prof: not yet rated

Pfizer Inc. (NYSE: PFE) today announced results from a Phase 3 12-week efficacy sub-study, which found that PRISTIQ� (desvenlafaxine), a serotonin-norepinephrine reuptake inhibitor (SNRI), significantly reduced the number and severity of moderate-to-severe hot flashes in postmenopausal women. The data were presented at the 59th Annual Clinical Meeting of the American College of Obstetricians and Gynecologists in Washington, D.C.1

PRISTIQ, which is approved by the U.S. Food and Drug Administration (FDA) for the treatment of major depressive disorder (MDD) in adults, is a non-hormonal therapy currently under review by the FDA for the treatment of moderate-to-severe vasomotor symptoms (VMS) associated with menopause - commonly referred to as hot flashes and night sweats.2

"Desvenlafaxine significantly reduced the number and severity of moderate-to-severe hot flashes among postmenopausal women compared with placebo, which is meaningful because up to 75 percent of women experience hot flashes associated with menopause,"1,3 said JoAnn V. Pinkerton, M.D., lead author for the efficacy sub-study and Medical Director of Midlife Health Center and Professor of Obstetrics and Gynecology, University of Virginia.1

Women can experience hot flashes associated with menopause for varying periods of time, typically ranging from six months to a few years.3

"Pfizer is committed to women's health and understands the impact that hot flashes and night sweats related to menopause can have on a woman's life and the importance of having options to treat menopausal symptoms," said Steven Romano, M.D., senior vice president and head, Medicines Development Group, Primary Care Business Unit, Pfizer. "If approved by the FDA for this indication, PRISTIQ will expand the range of effective treatment options available to help manage VMS in the United States."

More About the Efficacy Sub-study

The efficacy sub-study of 365 patients was part of a year-long, double-blind, placebo-controlled safety trial conducted in the United States and Canada. Patients enrolled in the efficacy sub-study were required to have at least 7 bothersome moderate-to-severe hot flashes per day or 50 bothersome moderate-to-severe hot flashes per week at baseline.1 In the efficacy sub-study, desvenlafaxine met all four co-primary endpoints - the change from baseline in both the number and severity of moderate-to-severe hot flashes at week 4 and at week 12 (all p<0.001 versus placebo).1

At week 4 of this efficacy sub-study, women in the PRISTIQ-treated group experienced a 55 percent reduction in hot flash frequency (average decrease of 6.5 hot flashes/day from a baseline mean of approximately 12 hot flashes/day) contrasted with a 31 percent reduction in hot flash frequency (average decrease of 3.6 hot flashes/day from a baseline mean of approximately 12 hot flashes/day) in the placebo group. At week 12, women in the PRISTIQ-treated group experienced a 62 percent reduction in hot flash frequency (average decrease of 7.3 hot flashes/day from a baseline mean of approximately 12 hot flashes/day) contrasted with a 38 percent reduction in hot flash frequency (average decrease of 4.5 hot flashes/day from a baseline mean of approximately 12 hot flashes/day) in the placebo group.1

Women in the PRISTIQ-treated group also experienced a 20 percent reduction in the severity of their hot flashes contrasted with an 8 percent reduction in the placebo group at week 4 of this efficacy sub-study. At week 12, women in the PRISTIQ-treated group experienced a 25 percent reduction in the severity of their hot flashes contrasted with a 12 percent reduction in the placebo group.1

During the 12-week efficacy sub-study, the most commonly reported adverse events were nausea, dry mouth, fatigue, constipation, diarrhea and somnolence.1 Ten percent of the PRISTIQ-treated patients and 3.7 percent of the placebo-treated patients discontinued the study early due to adverse events.1 A total of 2.5 percent of the PRISTIQ-treated patients and 8.4 percent of the placebo-treated patients discontinued due to lack of efficacy.1

About PRISTIQ Extended Release Tablets

PRISTIQ is a prescription medicine approved by the FDA for the treatment of major depressive disorder (MDD). PRISTIQ belongs to a class of medicines known as serotonin-norepinephrine reuptake inhibitors (or SNRIs). PRISTIQ is not approved for use in children and adolescents less than 18 years of age.

Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, teens, and young adults. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior when initiating or changing their dose of antidepressant therapy.

Patients taking MAOIs should not take PRISTIQ. Patients being considered for PRISTIQ therapy should discuss all of the medicines that they are taking with their health care provider including medicines for migraines or psychiatric disorders to avoid a potentially life-threatening condition, as well as aspirin, non-steroidal anti-inflammatory drugs (NSAIDS), or blood thinners because co-administration of PRISTIQ with these drugs may increase the risk of bleeding.

PRISTIQ may cause or make some conditions worse including high blood pressure, which should be controlled before starting PRISTIQ and monitored regularly during PRISTIQ therapy, glaucoma or increased eye pressure, mania, bipolar disorder, high cholesterol or triglyceride levels, stroke, heart problems, kidney or liver problems, seizures or convulsions, and low sodium levels.

Discontinuation symptoms may occur when stopping or reducing PRISTIQ. Side effects when taking PRISTIQ 50 mg may include nausea, dizziness, sweating, constipation, and decreased appetite.

1 Pinkerton JV, Constantine G, Hwang E, Cheng RJ. Desvenlafaxine efficacy vs placebo for the treatment of menopausal vasomotor symptoms. Poster presented at: 59th Annual Clinical Meeting of the American College of Obstetricians and Gynecologists (ACOG); April 30 - May 3, 2011; Washington, D.C.

2 North American Menopause Society. Menopause glossary. Accessed February 23, 2011.

3 North American Menopause Society. Clinical issues. In: Menopause Practice: A Clinician's Guide. 4th ed. Mayfield Heights, OH: North American Menopause Society; 2010:4-9.

Source:
Pfizer Inc.

Please rate this article:
(Hover over the stars
then click to rate)		 Patient / Public:
 or Health Professional:
Bookmark and Share

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:




Privacy Policy | Terms and Conditions

MediLexicon International Ltd
Bexhill-on-Sea, UK
MediLexicon International Ltd � 2004-2011 All rights reserved.


Source: http://www.medicalnewstoday.com/articles/224199.php

health insurance pregnant women women & health 2 womens health video mental health women women health tips

Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)